P90 ribosomal S6 kinase regulates activity of the renin-angiotensin system: A pathogenic mechanism for ischemia-reperfusion injury

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 2, 2011, Pages 272-275

  Shi, Xi ^a   Yan, Chen ^a   Nadtochiy, Sergiy M ^a   Abe, Jun Ichi ^a   Brookes, Paul S ^a   Berk, Bradford C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Aliskiren; Ischemia reperfusion; Renin; Renin angiotensin system; RSK

Indexed keywords

ALISKIREN; MESSENGER RNA; RENIN; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISOLATED HEART; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSGENIC MOUSE;

AMIDES; ANIMALS; FUMARATES; GENE EXPRESSION REGULATION; HEART; MICE; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCARDIUM; RENIN; RENIN-ANGIOTENSIN SYSTEM; REPERFUSION INJURY; RIBOSOMAL PROTEIN S6 KINASES; RNA, MESSENGER;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 79959492923     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.05.005     Document Type: Article

References (15)

1. Brown M.J. Aliskiren Circ 2008, 118(7):773-784.
2. Endo-Mochizuki Y., Mochizuki N., Sawa H., Takada A., Okamoto H., Kawaguchi H., et al. Expression of renin and angiotensin-converting enzyme in human hearts. Heart Vessels 1995, 10(6):285-293.
3. van Kats J.P., Danser A.H., van Meegen J.R., Sassen L.M., Verdouw P.D., Schalekamp M.A. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998, 98(1):73-81.
4. Zolk O., Flesch M., Schnabel P., Teisman A.C., Pinto Y.M., van Gilst W.H., et al. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats. Br J Pharmacol 1998, 123(3):405-412.
5. Itoh S., Ding B., Shishido T., Lerner-Marmarosh N., Wang N., Maekawa N., et al. Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation 2006 Apr 11, 113(14):1787-1798.
6. Westermann D., Riad A., Lettau O., Roks A., Savvatis K., Becher P.M., et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension 2008, 52(6):1068-1075.
7. Takeishi Y., Huang Q., Abe J., Che W., Lee J.D., Kawakatsu H., et al. Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc Res 2002, 53(1):131-137.
8. Maekawa N., Abe J., Shishido T., Itoh S., Ding B., Sharma V.K., et al. Inhibiting p90 ribosomal S6 kinase prevents Na+-H+exchanger-mediated cardiac ischemia-reperfusion injury. Circulation 2006 May 30, 113(21):2516-2523.
9. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008 Jun 5, 358(23):2433-2446.
10. McMurray J.J., Pitt B., Latini R., Maggioni A.P., Soloman S.D., Keefe D.L., et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation 2008, 1:17-24.
11. Solomon S.D., Appelbaum E., Manning W.J., Verma A., Berglund T., Lukashevich V., et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation Jan 19 2009.
12. Duprez D.A., Davis P., Botha J. The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients 65 years of age with systolic hypertension. Circulation 2008, 118:S886-S887.
13. Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant May 2009, 24(5):1663-1671.
14. Krum H., Massie B., Abraham W.T., Dickstein K., Kober L., McMurray J.J., et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011, 13(1):107-114.
15. Gheorghiade M., Albaghdadi M., Zannad F., Fonarow G.C., Böhm M., Gimpelewicz C., et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011, 13(1):100-106.